Therapeutics News and Research

RSS

Overcoming cancer relapse with CAR-Enhancer therapy

Even as they have revolutionized the treatment of certain forms of cancer, CAR T-cell therapies have been shadowed by a significant limitation: many patients, including those whose cancer goes into full remission, eventually relapse. In a new study, Dana-Farber Cancer Institute researchers report on a technique with the potential to eliminate that problem.

26 Jul 2024

UQ opens new facility for personalized mRNA cancer vaccine development

A new facility at The University of Queensland is set to provide Australian researchers with cancer vaccines tailored to individual patients.

25 Jul 2024

UK initiative aims to transform MND research through health data collaboration

MND is a devastating disease affecting the motor neurones in the brain and spinal cord, leading to progressive muscle weakness and paralysis.

25 Jul 2024

Experimental cancer drug could make thinking easier for individuals with Rett syndrome

An experimental cancer drug could make thinking easier for individuals with Rett syndrome, a rare disorder linked to autism, according to new research from the University of California San Diego -; a discovery that could lead to therapies for patients with other neurological conditions.

25 Jul 2024

Unveiling the healing power of Alcaligenes faecalis in diabetic wounds

There are many important reasons for keeping cuts and sores clean, but new research from the Perelman School of Medicine at the University of Pennsylvania shows that a certain bug,

25 Jul 2024

MD Anderson and Summit Therapeutics partner to accelerate ivonescimab development

The University of Texas MD Anderson Cancer Center and Summit Therapeutics, Inc. today announced a strategic five-year collaboration agreement for the purpose of accelerating the development of ivonescimab.

25 Jul 2024

Study highlights infection as major post-CAR-T therapy challenge

In patients with diffuse large B-cell non-Hodgkin lymphoma (DLBCL), the two hallmark post-chimeric antigen receptor (CAR)-T therapy toxicities are extremely rare after two weeks, supporting a shorter, more flexible toxicity monitoring period, according to a study published in Blood Advances.

25 Jul 2024

Neuroscientists discover a key piece of the placebo effect puzzle

The placebo effect is very real. This we've known for decades, as seen in real-life observations and the best double-blinded randomized clinical trials researchers have devised for many diseases and conditions, especially pain.

24 Jul 2024

Creating the first genetically susceptible mice for late-onset Alzheimer's

Mice don't get Alzheimer's-;and while that's good news for mice, it's a big problem for biomedical researchers seeking to understand the disease and test new treatments.

24 Jul 2024

Enterprise Therapeutics doses first person with cystic fibrosis in Phase 2 trial for novel therapy ETD001

Enterprise Therapeutics Ltd (Enterprise), a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of those suffering from respiratory disease, today announced dosing of the first person with cystic fibrosis (pwCF) in its Phase 2a trial of ETD001.

24 Jul 2024

More types of lung cells can be infected by SARS-CoV-2 than previously thought, scientists report

Scientists at Sanford Burnham Prebys, University of California San Diego and their international collaborators have reported that more types of lung cells can be infected by SARS-CoV-2 than previously thought, including those without known viral receptors.

23 Jul 2024

Lario Therapeutics awarded $6M Grant from The Michael J. Fox Foundation for Parkinson’s Research

Award supports preclinical research of Lario’s CaV2.3 calcium channel inhibitors as a novel disease-modifying approach for treatment of Parkinson's disease.

23 Jul 2024

New strategy for mRNA nanocarriers using triphenyl phosphonium

Among the vastly different ways of tackling a disease, controlling the genetic expression of cells is undoubtedly one of the most powerful. Over the past few decades, scientists have come up with dozens of innovative strategies that involve using messenger RNA (mRNA) to 'force' cells to build specific proteins. These mRNA-based therapies have recently gained prominence as vaccines against infectious diseases like COVID-19. Additionally, they hold significant potential for treating cancer and genetic disorders.

23 Jul 2024

Synthetic solutions for ethical and effective drug testing

Improving human quality of life with drug treatments is a complicated issue. Drug certification, including drug safety and reliability, entails a long series of tests and government approvals before the drug is available for anyone to use.

22 Jul 2024

Duke-NUS unveils LIVE Ventures to catalyze the commercialization of academic research

Duke-NUS Medical School today launched LIVE Ventures, a S$20 million incubation programme designed to catalyse the commercialisation of innovative academic research.

22 Jul 2024

Unexpected T-cell reactions to adenoviral COVID-19 vaccines discovered

Researchers from the University of Liverpool's Centre for Drug Safety Science have identified unpredicted T-cell immune responses to the adenoviral (Oxford/AstraZeneca and Janssen) COVID-19 vaccines, but not to the mRNA vaccines.

19 Jul 2024

Feline gut microbes shed light on obesity treatment for humans

Pet cats may be excellent animal models for the study of obesity origins and treatment in humans, a new study of feline gut microbes suggests – and both species would likely get healthier in the research process, scientists say.

18 Jul 2024

Breakthrough gene therapy offers hope for Duchenne muscular dystrophy

A new gene therapy treatment for Duchenne muscular dystrophy shows promise of not only arresting the decline of the muscles of those affected by this inherited genetic disease, but perhaps, in the future, repairing those muscles.

18 Jul 2024

Llama-derived molecules target hidden strains of HIV

A research team at Georgia State University has developed tiny, potent molecules that are capable of targeting hidden strains of HIV. The source? Antibody genes from llama DNA.

17 Jul 2024

Spinal Muscular Atrophy patients are at higher risk of developing fatty liver disease

An international study has discovered that people living with the neurodegenerative condition Spinal Muscular Atrophy (SMA) are at higher risk of developing fatty liver disease, suggesting that SMA patients may face additional health problems over time.

17 Jul 2024